Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer

被引:2
|
作者
Liu, Yue-E [1 ]
Xue, Xiao-Ying [2 ]
Zhang, Rui [1 ]
Chen, Xue-Ji [1 ]
Ding, Yu-Xia [1 ]
Liu, Chao-Xing [3 ]
Qin, Yue-Liang [1 ]
Li, Wei-Qian [1 ]
Ren, Xiao-Cang [1 ]
Lin, Qiang [1 ,4 ]
机构
[1] Hebei Med Univ, North China Petr Bur Gen Hosp, Dept Oncol, Renqiu, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 2, Dept Radiotherapy, Shijiazhuang, Hebei, Peoples R China
[3] 1 Hosp Shijiazhuang City, Dept Oncol, Shijiazhuang, Hebei, Peoples R China
[4] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China
来源
BMJ OPEN | 2020年 / 10卷 / 10期
关键词
oncology; radiotherapy; respiratory tract tumours; RADIATION-DOSE PRESCRIPTION; CONFORMAL RADIOTHERAPY; ESCALATION; CHEMOTHERAPY; CONSTRAINTS; DOCETAXEL; THERAPY; VOLUME;
D O I
10.1136/bmjopen-2019-036295
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Concurrent chemoradiotherapy with conventional fractionation has been acknowledged as one of the standard treatments for locally advanced non-small cell lung cancer (NSCLC). The radiotherapy dose of 60 Gy is far from enough for local tumour control. Due to this fact, hypofractionated radiotherapy can shorten the total treatment duration, partially counteract the accelerated repopulation of tumour cells and deliver a higher biological effective dose, it has been increasingly used for NSCLC. In theory, concurrent hypofractionated chemoradiotherapy can result in an enhanced curative effect. To date, the vast majority of radiotherapy prescriptions assign a uniform radiotherapy dose to all patients. However this kind of uniform radiotherapy prescription may lead to two consequences: excess damage to normal tissues for large tumours and insufficient dose for small tumours. Our study aims to evaluate whether delivering individualised radiotherapy dose is feasible using intensity-modulated radiotherapy. Methods and analysis Our study of individualised radiotherapy is a multicenter phase II trial. From April 2019, a total of 30 patients from three Chinese centres, with a proven histological or cytological diagnosis of inoperable NSCLC, will be recruited. The dose of radiation will be increased until one or more of the organs at risk tolerance or the maximum dose of 69 Gy is reached. The primary end point is feasibility, with response rates, progression-free survival and overall survival as secondary end points. The concurrent chemotherapy regimen will be docetaxel plus lobaplatin. Ethics and dissemination The study has been approved by medical ethics committees from three research centres. The trial is conducted in accordance with the Declaration of Helsinki. The trial results will be disseminated through academic conference presentations and peer-reviewed publications.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Hypofractionated irradiation for non-small cell lung cancer
    Abratt, RP
    Bogart, JA
    Hunter, A
    LUNG CANCER, 2002, 36 (03) : 225 - 233
  • [32] Concomitant ChemoRadiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study from the Galician Lung Cancer Group
    Gomez, Susana
    Areses, Carmen
    Fernandez, Natalia
    Garcia, Jorge
    Costa, Marinha
    Firvida, Jose Luis
    Campos, Begona
    Hernandez, Elena
    Taboada, Begona
    Castro, Enrique
    Veiras, Maria
    Afonso, Javier
    Azpitarte, Cristina
    Amenedo, Margarita
    Casal Rubio, Joaquin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S864 - S865
  • [33] Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
    Kang, Ki Mun
    Jeong, Bae Kwon
    Ha, In Bong
    Chai, Gyu Young
    Lee, Gyeong Won
    Kim, Hoon Gu
    Kang, Jung Hoon
    Lee, Won Seob
    Kang, Myoung Hee
    RADIATION ONCOLOGY JOURNAL, 2012, 30 (03): : 140 - 145
  • [34] Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial
    Fu, Zhixue
    Yang, Xu
    Wang, Wenqing
    Deng, Lei
    Zhang, Tao
    Bi, Nan
    Wang, Xiaozhen
    Chen, Dongfu
    Zhou, Zongmei
    Wang, Luhua
    Liang, Jun
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [35] Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial
    Zhixue Fu
    Xu Yang
    Wenqing Wang
    Lei Deng
    Tao Zhang
    Nan Bi
    Xiaozhen Wang
    Dongfu Chen
    Zongmei Zhou
    Luhua Wang
    Jun Liang
    Radiation Oncology, 15
  • [36] A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401
    Oh, In-Jae
    Kim, Kyu-Sik
    Kim, Young-Chul
    Ban, Hee-Jung
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Chung, Woong-Ki
    Nam, Taek-Keun
    Song, Joo-Young
    Yoon, Mee-Sun
    Ahn, Sung-Ja
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1247 - 1254
  • [37] A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401
    In-Jae Oh
    Kyu-Sik Kim
    Young-Chul Kim
    Hee-Jung Ban
    Yong-Soo Kwon
    Yu-Il Kim
    Sung-Chul Lim
    Woong-Ki Chung
    Taek-Keun Nam
    Joo-Young Song
    Mee-Sun Yoon
    Sung-Ja Ahn
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1247 - 1254
  • [38] Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer
    Naito, Yoichi
    Kubota, Kaoru
    Nihei, Keiji
    Fujii, Tomonori
    Yoh, Kiyotaka
    Niho, Seiji
    Goto, Koichi
    Ohmatsu, Hironobu
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : 617 - 622
  • [39] A therapeutic radiographer perspective of concurrent chemoradiotherapy for non-small cell lung cancer in the UK
    Maguire, Caroline
    Finn, David
    Bell, Lynn
    Bewley, Michelle
    Kirby, Rachel
    Moore, Karen
    Mccrimmon, Deborah
    Pickles, Rebecca
    Sharma, Catherine
    Stamp, Alexander
    White, Lindsey
    Wingate, Emma
    Wooder, Rachel
    LUNG CANCER, 2025, 200
  • [40] Concurrent chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer
    Song, X
    Gallant, V
    Laurie, S
    Nicholas, G
    Reaume, N
    MacRae, R
    Agboola, O
    Perry, G
    Lochrin, C
    Goss, G
    LUNG CANCER, 2005, 49 : S174 - S175